Transcriptomic Heterogeneity of Favorable-risk Prostate Cancer: Time To Move Past Cancer of the Prostate Risk Assessment (CAPRA) to Clinical-genomic Risk

被引：1
|
作者：
Spratt, Daniel E. [1 ]
Schaeffer, Edward M. [2 ]
机构：
[1] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA
[2] Northwestern Univ, Feinberg Sch Med, Dept Urol, 300 E Super, Chicago, IL 60611 USA
来源：
EUROPEAN UROLOGY | 2018年 / 74卷 / 04期
关键词：
CLASSIFICATION; METASTASIS; RADIATION; MORTALITY;
D O I：
10.1016/j.eururo.2018.06.001
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：453 / 454
页数：2
相关论文
共 50 条
  • [31] Active Surveillance for Favorable-risk Prostate Cancer: Background, Patient Selection, Triggers for Intervention, and Outcomes
    Laurence Klotz
    Current Urology Reports, 2012, 13 : 153 - 159
  • [32] Comorbidity and the receipt of curative therapy for favorable-risk prostate cancer prior to and following the publication of PIVOT
    Mihalcik, Stephen A.
    Chen, Ming-Hui
    Braccioforte, Michelle H.
    Moran, Brian Joseph
    D'Amico, Anthony V.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [33] Re: Impact of a Genomic Test on Treatment Decision in a Predominantly African American Population with Favorable-Risk Prostate Cancer: A Randomized Trial
    Murphy, A. B.
    Abern, M. R.
    Liu, L.
    Wang, H.
    Hollowell, C. M. P.
    Sharifi, R.
    Vidal, P.
    Kajdacsy-Balla, A.
    Sekosan, M.
    Ferrer, K.
    Wu, S.
    Gallegos, M.
    King-Lee, P.
    Sharp, L. K.
    Ferrans, C. E.
    Gann, P. H.
    JOURNAL OF UROLOGY, 2021, 206 (06): : 1507 - 1508
  • [34] Multiparametric magnetic resonance imaging for prostate cancer improves Gleason score assessment in favorable risk prostate cancer
    Kamrava, Mitchell
    Kishan, Amar U.
    Margolis, Daniel J.
    Huang, Jiaoti
    Dorey, Fred
    Lieu, Patricia
    Kupelian, Patrick A.
    Marks, Leonard S.
    PRACTICAL RADIATION ONCOLOGY, 2015, 5 (06) : 411 - 416
  • [35] Prostate Cancer Tumor Volume and Genomic Risk
    Ramaswamy, Ashwin
    Proudfoot, James A.
    Ross, Ashley E.
    Davicioni, Elai
    Schaeffer, Edward M.
    Hu, Jim C.
    EUROPEAN UROLOGY OPEN SCIENCE, 2023, 48 : 90 - 97
  • [36] Risk of missing advanced stage or high grade tumors during active surveillance (AS) even in favorable-risk prostate cancer (PC)
    Kim, Jeri
    Ward, John Francis
    Pettaway, Curtis A.
    Wang, Xuemei
    Kuban, Deborah A.
    Frank, Steven J.
    Lee, Andrew
    Pisters, Louis L.
    Matin, Surena F.
    Shah, Jay Bakul
    Karam, Jose A.
    Chapin, Brian Francis
    Papadopoulos, John N.
    Achim, Mary F.
    Hoffman, Karen Elizabeth
    Pugh, Thomas J.
    Choi, Seungtaek
    Logothetis, Christopher
    Troncoso, Patricia
    Davis, John W.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [37] Individualized risk assessment for prostate cancer
    Nature Clinical Practice Oncology, 2006, 3 (7): : 350 - 350
  • [38] A Roadmap for Improving the Management of Favorable Risk Prostate Cancer
    Auffenberg, Gregory B.
    Lane, Brian R.
    Linsell, Susan
    Brachulis, Andrew
    Ye, Zaojun
    Rakic, Nikola
    Montie, James
    Miller, David C.
    Cher, Michael L.
    JOURNAL OF UROLOGY, 2017, 198 (06): : 1221 - 1223
  • [39] Active Surveillance for Favorable Risk Prostate Cancer PRO
    Klotz, Laurence
    JOURNAL OF UROLOGY, 2009, 182 (06): : 2565 - 2566
  • [40] Individualized risk assessment for prostate cancer
    Nature Clinical Practice Urology, 2006, 3 (7): : 354 - 354
12345